XML 68 R56.htm IDEA: XBRL DOCUMENT
v3.20.4

Note 9 - Fair Value Considerations (Details Textual) shares in Thousands |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Mar. 31, 2020 USD ($) shares | Feb. 14, 2020 USD ($) shares | Nov. 30, 2021 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2019 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2019 USD ($) | Jun. 30, 2020 USD ($) | Nov. 02, 2018 USD ($) | Jun. 11, 2018 USD ($)
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability |  |  |  | $ 3,313,656 |  | $ 2,411,333 |  |  |  |
Gain (Loss) from Change in Fair Value of CVR |  |  |  |  |  | (899,987) |  |  |  |
Tuzistra XR [Member] |  |  |  |  |  |  |  |  |  |
Business Combination, Contingent Consideration, Liability, Total |  |  |  | 15,800,000 |  | 15,800,000 |  |  | $ 8,800,000 |
Tuzistra XR [Member] | Forecast [Member] |  |  |  |  |  |  |  |  |  |
Payment for Contingent Consideration Liability, Operating Activities |  |  | $ 3,000,000 |  |  |  |  |  |  |
ZolpiMist [Member] |  |  |  |  |  |  |  |  |  |
Business Combination, Contingent Consideration, Liability, Total |  |  |  | 300,000 |  | 300,000 |  |  |  | $ 2,600,000
Innovus Pharmaceuticals [Member] |  |  |  |  |  |  |  |  |  |
Business Combination, Contingent Consideration, Liability, Total |  | $ 200,000 |  |  |  |  |  |  |  |
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability |  |  |  | 15,000 | 15,000 | 28,000 | 28,000 |  |  |
Business Combination, Contingent Value Rights, Maximum Range of Outcomes |  | $ 16,000,000 |  |  |  |  |  |  |  |
Business Combination, Maximum Shares to be Issued to Settle CVR (in shares) | shares |  | 470 |  |  |  |  |  |  |  |
Stock Issued During Period, Shares, Contingent Value Rights (in shares) | shares | 120 |  |  |  |  |  |  |  |  |
Stock Issued During Period, Value, Contingent Value Rights | $ 2,000,000 |  |  |  |  |  |  |  |  |
Business Combination, Contingent Value Rights, First Revenue Milestone | 24,000,000 |  |  |  |  |  |  |  |  |
Gain (Loss) from Change in Fair Value of CVR | $ 300,000 |  |  | $ (100,000) | $ (100,000) | $ (800,000) | $ (800,000) | $ 300,000 |  |
Innovus Pharmaceuticals [Member] | Measurement Input, Discount Rate [Member] |  |  |  |  |  |  |  |  |  |
Business Combination, Contingent Consideration, Liability, Measurement Input |  | 0.3 |  |  |  |  |  |  |  |

X
- Definition The first revenue milestone for contingent value rights of the business acquisition. + References No definition available. + Details
Name: | aytu_BusinessCombinationContingentValueRightsFirstRevenueMilestone
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The maximum amount of contingent value rights of the business combination. + References No definition available. + Details
Name: | aytu_BusinessCombinationContingentValueRightsMaximumRangeOfOutcomes
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The maximum number of shares that would be issued to settle the contingent value rights issued in the business acquisition. + References No definition available. + Details
Name: | aytu_BusinessCombinationMaximumSharesToBeIssuedToSettleCVR
Namespace Prefix: | aytu_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of gain (loss) from change in fair value of CVR. + References No definition available. + Details
Name: | aytu_GainLossFromChangeInFairValueOfCVR
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The number of shares of stock issued during the period for contingent value rights. + References No definition available. + Details
Name: | aytu_StockIssuedDuringPeriodSharesContingentValueRights
Namespace Prefix: | aytu_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The value of stock issued during the period for contingent value rights. + References No definition available. + Details
Name: | aytu_StockIssuedDuringPeriodValueContingentValueRights
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 4 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Value of input used to measure contingent consideration liability from business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput
Namespace Prefix: | us-gaap_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 17 -Subparagraph (ee) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585 + Details
Name: | us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=aytu_TuzistraXrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=aytu_ZolpimistMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=aytu_InnovusPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |